{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:21:47Z","timestamp":1788186107189,"version":"build-2803163510"},"reference-count":41,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,3,16]]},"DOI":"10.1080\/14796694.2025.2461430","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T02:02:05Z","timestamp":1740621725000},"page":"853-865","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Patient preferences for triple-class\u2013exposed relapsed or refractory multiple myeloma treatment: a discrete-choice study"],"prefix":"10.1080","volume":"21","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[{"name":"Mayo Clinic","place":["Jacksonville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3394-4078","authenticated-orcid":false,"given":"Timothy J.","family":"Inocencio","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3144-8938","authenticated-orcid":false,"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[{"name":"Research Triangle Park","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2526-8674","authenticated-orcid":false,"given":"Phani","family":"Chintakayala","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cooper","family":"Bussberg","sequence":"additional","affiliation":[{"name":"Research Triangle Park","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chi","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4217-0118","authenticated-orcid":false,"given":"James","family":"Harnett","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2897-9810","authenticated-orcid":false,"given":"Glenn S.","family":"Kroog","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Rodriguez-Lorenc","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc","place":["Tarrytown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2586"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5467-x"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25764"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.05.019"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000404"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.621"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29070355"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07018-6"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocm.2015.09.001"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11539650-000000000-00000"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511753831"},{"key":"e_1_3_8_16_1","unstructured":"PREFER Consortium. PREFER Recommendations - Why when and how to assess and use patient preferences in medical product decision-making [Internet]. 2022 [cited 2024 Jul 1]. Available from: https:\/\/www.imi-prefer.eu\/w\/ip"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S345906"},{"key":"e_1_3_8_18_1","first-page":"Doc10","article-title":"Evaluating patients\u2019 preferences for multiple myeloma therapy, a discrete-choice-experiment","volume":"5","author":"M\u00fchlbacher AC","year":"2008","unstructured":"M\u00fchlbacher AC, Lincke HJ, N\u00fcbling M. Evaluating patients\u2019 preferences for multiple myeloma therapy, a discrete-choice-experiment. Psychosoc Med. 2008;5:Doc10.","journal-title":"Psychosoc Med"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S183187"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0378"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1027353"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-010-0218-6"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.12.012"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1271657"},{"key":"e_1_3_8_25_1","unstructured":"Carvykti PI. Janssen Biotech Inc. Carvykti prescribing information [Internet]. 2023 [cited 2023 Feb 28]. Available from: https:\/\/www.fda.gov\/media\/156560\/download"},{"key":"e_1_3_8_26_1","unstructured":"Abecma PI. Bristol-Myers Squibb. Abecma prescribing information [Internet]. 2021 Mar [cited 2023 Feb 28]. Available from: https:\/\/www.fda.gov\/media\/147055\/download"},{"key":"e_1_3_8_27_1","unstructured":"Tecvayli PI. Janssen Biotech Inc. Tecvayli prescribing information [Internet]. 2022 Oct [cited 2023 Feb 28]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.01.012"},{"key":"e_1_3_8_29_1","volume-title":"Marketing research methods in SAS experimental design, choice, conjoint, and graphical techniques","author":"Kuhfeld W","year":"2010","unstructured":"Kuhfeld W. Marketing research methods in SAS experimental design, choice, conjoint, and graphical techniques. Cary, NC, USA: SAS Institute Inc; 2010."},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.2307\/3151882"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.11.013"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2016.04.004"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.08.2223"},{"key":"e_1_3_8_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008"},{"key":"e_1_3_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7540"},{"key":"e_1_3_8_36_1","unstructured":"Elrexfio PI. Pfizer Inc. Elrexfio prescribing information [Internet]. 2023 [cited 2024 Aug 1]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf"},{"key":"e_1_3_8_37_1","volume-title":"Presented at EHA2024\u00a0Hybrid Congress","author":"Mohty M","unstructured":"Mohty M, Iida S, Bahlis NJ, et al. Long-term survival after elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM): MAGNETISMM-3. Presented at EHA2024\u00a0Hybrid Congress; Madrid, Spain; 2024 Jun 13\u201316."},{"key":"e_1_3_8_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8016"},{"key":"e_1_3_8_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.380"},{"key":"e_1_3_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.01.016"},{"key":"e_1_3_8_42_1","unstructured":"US Food and Drug Administration. Patient preference information \u2013 voluntary submission review in premarket approval applications humanitarian device exemption applications and de novo requests and inclusion in decision summaries and device labeling. [Internet]. 2016 Aug 24 [cited 2024 Jul 1]. Available from: https:\/\/www.fda.gov\/media\/92593\/download"},{"key":"e_1_3_8_43_1","volume-title":"Presented at Society of Hematologic Oncology","author":"Ailawadhi S","year":"2024","unstructured":"Ailawadhi S, Inocencio TJ, Mansfield C, et al. Preferences among patients with triple class\u2013exposed relapsed\/refractory multiple myeloma in the era of B-cell maturation antigen\u2013directed T-cell\u2013engaging therapies. Presented at Society of Hematologic Oncology; Houston, (TX), USA; 2024 Sep 4\u20137."}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2461430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:36:19Z","timestamp":1762958179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2461430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,3,16]]}},"alternative-id":["10.1080\/14796694.2025.2461430"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2461430","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-11-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}